Search research articles
Contact Us
Filters
Showing results (471-480 of 529) with videos related to
Page
of 53
Sort By:
Hematological Oncology
|
November 24, 2022
Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes
Wan-Hsuan Lee, Chien-Chin Lin, Yu-Hung Wang, et al.
Haematologica
|
August 25, 2022
Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia
Binay K Sahoo, Yuh-Charn Lin, Cheng-Fen Tu, et al.
Blood Research
|
June 2, 2026
Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations
Yun-Tzu Lin, Xavier Cheng-Hong Tsai, Feng-Ming Tien, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 19, 2025
Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study
Yu-Sung Chang, Chieh-Yu Liu, Yu-Wen Chen, et al.
Cancer Research
|
January 11, 2017
Aurora A and NF-κB Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA
Tong-You Wade Wei, Pei-Yu Wu, Ting-Jung Wu, et al.
Ebiomedicine
|
January 22, 2019
Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients
Cheng-Hong Tsai, Chi-Yuan Yao, Feng-Min Tien, et al.
Blood Cancer Journal
|
January 6, 2026
Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data
Yu-Sung Chang, Feng-Ming Tien, Yu-Wen Wang, et al.
Blood Advances
|
May 17, 2021
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML
Cheng-Hong Tsai, Jih-Luh Tang, Feng-Ming Tien, et al.
Blood
|
August 2, 2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
Eunice S Wang, Pau Montesinos, Mark D Minden, et al.
Blood
|
October 8, 2009
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations
Jih-Luh Tang, Hsin-An Hou, Chien-Yuan Chen, et al.
Page
of 53
Search research articles
Search
Showing results (471-480 of 529) with videos related to
Sort By:
Page
of 53
Hematological Oncology
|
November 24, 2022
Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes
Wan-Hsuan Lee, Chien-Chin Lin, Yu-Hung Wang, et al.
Haematologica
|
August 25, 2022
Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia
Binay K Sahoo, Yuh-Charn Lin, Cheng-Fen Tu, et al.
Blood Research
|
June 2, 2026
Real-world experience with gilteritinib maintenance following allogeneic transplantation in relapsed/refractory AML patients harboring FLT3 mutations
Yun-Tzu Lin, Xavier Cheng-Hong Tsai, Feng-Ming Tien, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 19, 2025
Real-World Evidence on Outcomes and Safety of Ropeginterferon Alfa-2b in Patients With Myeloproliferative Neoplasms: A Retrospective Cohort Study
Yu-Sung Chang, Chieh-Yu Liu, Yu-Wen Chen, et al.
Cancer Research
|
January 11, 2017
Aurora A and NF-κB Survival Pathway Drive Chemoresistance in Acute Myeloid Leukemia via the TRAF-Interacting Protein TIFA
Tong-You Wade Wei, Pei-Yu Wu, Ting-Jung Wu, et al.
Ebiomedicine
|
January 22, 2019
Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients
Cheng-Hong Tsai, Chi-Yuan Yao, Feng-Min Tien, et al.
Blood Cancer Journal
|
January 6, 2026
Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data
Yu-Sung Chang, Feng-Ming Tien, Yu-Wen Wang, et al.
Blood Advances
|
May 17, 2021
Clinical implications of sequential MRD monitoring by NGS at 2 time points after chemotherapy in patients with AML
Cheng-Hong Tsai, Jih-Luh Tang, Feng-Ming Tien, et al.
Blood
|
August 2, 2022
Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy
Eunice S Wang, Pau Montesinos, Mark D Minden, et al.
Blood
|
October 8, 2009
AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations
Jih-Luh Tang, Hsin-An Hou, Chien-Yuan Chen, et al.
Page
of 53